Armistice Capital Reduces Stake in Kura Oncology, Inc. Below 5% Threshold

Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A on May 15, 2026, disclosing a reduction in their position in Kura Oncology, Inc. (KURA). As of the event date of March 31, 2026, the reporting persons beneficially own 3,736,000 shares of common stock, representing a 4.23% ownership stake. This filing marks Amendment No. 5 to their previous disclosures. The shares are held directly by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC serving as the investment manager. Consequently, Armistice Capital and Mr. Boyd share voting and dispositive power over the reported shares. Because the ownership level has fallen below the 5% threshold, the reporting persons indicated that they are no longer beneficial owners of more than five percent of the issuer's outstanding common stock. The filing confirms that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.